Fosamprenavir (Lexiva, Telzir)
Overview
- A Clinical Overview of Fosamprenavir (Lexiva, Telzir) (Regularly Updated)
To read PDF, click here
From GlaxoSmithKline - Labeling Update for Lexiva (Fosamprenavir) (December 21, 2007)
From U.S. Food and Drug Administration - Prescribing Information for Fosamprenavir (Lexiva, Telzir) (PDF) (December 2007)
From GlaxoSmithKline - New Dosing Regimen for Fosamprenavir Approved: Ritonavir Dose Reduced (October 12, 2007)
From U.S. Food and Drug Administration - Fosamprenavir: A New Protease Inhibitor Option (February 2004)
An interview with Jeffrey Nadler, principal investigator of the pivotal NEAT study.
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care - FDA Approves Lexiva (Fosamprenavir Calcium) (October 21, 2003)
From U.S. Food and Drug Administration - Position Paper on 908 (Fosamprenavir, Lexiva) (October 13, 2003)
To read PDF, click here
In TAGline, from Treatment Action Group
Research & News
- Clinical Trials Using Fosamprenavir (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health - Literature Citations for Fosamprenavir (Regularly Updated)
From U.S. National Institutes of Health - GlaxoSmithKline Announces New Program to Provide Financial Assistance for Eligible HIV Patients in the U.S. (November 11, 2008)
Program reduces out-of-pocket expense burden for eligible patients on GSK HIV medications.
From GlaxoSmithKline - New Dosing Regimen for Fosamprenavir Approved: Ritonavir Dose Reduced (October 12, 2007)
From U.S. Food and Drug Administration - Agenerase (Amprenavir) Oral Solution and 50-mg Capsules to Be Discontinued in the U.S. (October 2007)
To read PDF, click here
From GlaxoSmithKline - FDA Approval of Lexiva Oral Suspension and Label Changes for Pediatric Patients and Patients With Hepatic Impairment (June 18, 2007)
From U.S. Food and Drug Administration - Fosamprenavir Efficacy and Safety on Par With Other PIs, With No Gender-Based Differences (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy - Potency of Boosted Fosamprenavir Matches Lopinavir/Ritonavir for First-Line Therapy (August 17, 2006)
In XVI International AIDS Conference - Pharmacokinetic Data Show That Fosamprenavir + Atazanavir Combination Should Not Be Used (February 6, 2006)
However, boosting with atazanavir instead of ritonavir does appear feasible, this study finds.
In The 13th Conference on Retroviruses and Opportunistic Infections - Rare Case of Protease Inhibitor Resistance After Failure of First-Line Boosted Fosamprenavir (December 17, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Lexiva: Blood Levels Not Lowered When Taken Simultaneously With Esomeprazole (Nexium) (June 20, 2005)
In AIDS Treatment News, from AIDS Treatment News - Don't Combine Fosamprenavir and Lopinavir/Ritonavir (February/March 2005)
From The Body PRO - Rash, NNRTIs and the 2NN Study (February/March 2005)
Rash appears more common among people taking nevirapine once a day.
From The Body PRO - Boosted Fosamprenavir Works Well as First-Line Therapy (July 23, 2004)
A HAART regimen containing fosamprenavir and ritonavir is highly effective and well-tolerated when used as first-line therapy in patients with advanced HIV, according to the final published results from this major study.
In AIDS - Fosamprenavir Update (July 13, 2004)
Recaps of studies on treatment-naive patients, switching from amprenavir and fosamprenavir resistance.
In The XV International AIDS Conference, from The Body PRO - Lexiva + Kaletra -- Still a Bad Idea (March/April 2004)
A short review of a study presented at CROI 2004.
In Positively Aware, from Test Positive Aware Network - The NEAT Study: A 48-Week Open-Label Study to Compare the Antiviral Efficacy and Safety of GW433908 Versus Nelfinavir in Antiretroviral Therapy-Naive HIV-1-Infected Patients (January 2004)
In Journal of Acquired Immune Deficiency Syndrome - Summary of Fosamprenavir Studies on Treatment-Naive and Protease Inhibitor-Experienced Patients (November 2003)
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Pharmacokinetic Interactions of 908 (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - 908 Plus Lopinavir/Ritonavir Does Not Appear to Be a Viable Regimen for HIV-Infected Patients (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - 908 vs. Kaletra: Comparable for Experienced Patients, Not for Naive (July 28, 2003)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Lower Rate of Resistance Seen in Boosted 908 Regimens (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Fosamprenavir: First Line or Later? (April 2003)
A summary of study results from CROI 2003.
In IAPAC Monthly, from International Association of Physicians in AIDS Care - The Context Study: Efficacy and Safety of GW433908/RTV in PI-Experienced Subjects With Virological Failure (24 Week Results) (February 14, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - The NEAT Study: GW433908 Efficacy and Safety in ART-Naive Subjects: Final 48-Week Analysis (February 14, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Effect of Amprenavir Hypersusceptibility on the Response to APV/Ritonavir-Based Therapy in ART-Experienced Adults Selected by Baseline Susceptibility (ESS40006): 24-Week Data (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - New Drug Holds Promise of Once-Daily Therapy (December 20, 2002)
From Canadian AIDS Treatment Information Exchange - Efficacy and Safety of GW433908/Ritonavir Once Daily in Therapy-Naive Subjects, 48-Week Results -- The SOLO Study (November 21, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO - GW433908, a Novel Prodrug of the HIV Protease Inhibitor (PI) Amprenavir (APV): Safety, Efficacy, and Pharmacokinetics (PK) (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - The NEAT Study: A 48-Week Open-Label Study to Compare the Antiviral Efficacy and Safety of GW433908 Versus Nelfinavir in Antiretroviral Therapy-Naive HIV-1-Infected Patients (February 2004)
Abstract of a pivotal study on fosamprenavir, published in JAIDS.
From International Association of Physicians in AIDS Care
Clinical Management
Clinical Management
  |